Company news

Silo Pharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Silo Pharma Announces Participation on Webull Corporate Communications Service Platform

June 1, 2023

Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21

May 29, 2023

Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease

May 8, 2023

Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders

April 18, 2023

Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia

March 26, 2023

Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia

March 14, 2023

Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s

February 12, 2023

Silo Pharma Announces Expansion of Intellectual Property Portfolio

February 1, 2023

Silo Pharma Announces Stock Repurchase Program

January 30, 2023

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

January 9, 2023

Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis

December 29, 2022

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

November 20, 2022

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

November 10, 2022

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

October 2, 2022

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option

September 29, 2022

Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq

September 14, 2022

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

July 26, 2022

Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients

July 11, 2022

Silo Pharma Expands License Agreement and Patent Portfolio

June 22, 2022

Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson’s Disease in Psilocybin Study

May 18, 2022

Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study

April 19, 2022

Silo Pharma Extends Exclusive Option Agreement for Homing Peptides

February 2, 2022

Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

December 1, 2021

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

November 17, 2021

Silo Pharma Reports Third Quarter Results and Operating Highlights

November 10, 2021

Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease

October 26, 2021

Silo Pharma achieves milestone - Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology

October 6, 2021

Silo Pharma Advances Psychedelic Patent Portfolio

August 24, 2021

Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research

August 10, 2021

Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent

July 26, 2021

Silo Pharma Enters into Sponsored Research Agreement with the University of Maryland, Baltimore

July 11, 2021

Silo Pharma extends agreement for experimental Rheumatoid Arthritis nanoparticle homing peptide

July 6, 2021

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients

June 7, 2021

Silo Pharma Submits Application for NASDAQ up-listing

May 24, 2021

Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.

May 12, 2021

Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics

April 27, 2021

Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

April 21, 2021

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

April 6, 2021

Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis

March 3, 2021

Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS

February 17, 2021

Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds

February 9, 2021

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

January 25, 2021

Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

January 12, 2021

Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications

January 10, 2021

Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

January 5, 2021

Silo Pharma, Inc. Enhances Scientific Advisory Board with Appointment of Dr. Charles B. Nemeroff of University of Texas at Austin

December 14, 2020

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

December 6, 2020

Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’s Disease

December 1, 2020

Silo Pharma, Inc. Expands Scientific Advisory Board with the Appointment of Dr. Joshua Woolley of University of California, San Francisco

November 15, 2020

Silo Pharma, Inc. Announces Filing of Three U.S. Provisional Patent Applications

November 11, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 6 decks. Every deck is listed under its year.